Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Nephrology

Monitoring Your Health and Looking Forward

At a Glance

For people with FSGS, achieving remission—especially a major reduction in urine protein—is linked with a better kidney outlook. Regular checks of urine protein, kidney filtering, blood pressure, and potassium guide care, while transplant recurrence risk depends on the FSGS type.

Living with Focal Segmental Glomerulosclerosis (FSGS) is a marathon, not a sprint. While the initial diagnosis can be frightening, long-term health is largely defined by how well the disease responds to treatment and how consistently you and your care team manage your kidney health day-to-day.

The Power of Remission

The single most important predictor of your long-term kidney health is achieving remission [1]. Remission means that the amount of protein leaking into your urine (proteinuria) has dropped significantly.

Doctors generally use two levels of remission to track progress [2][3]:

  • Complete Remission: Your protein levels drop to near-normal levels—often defined as a Urine Protein-to-Creatinine Ratio (UPCR) of less than 0.3 g/g [2].
  • Partial Remission: Your protein levels drop by at least 50% from where they started and stay roughly within the 0.3 to 3.5 g/g range [2].

Even if you do not reach complete remission, achieving a partial remission is a major victory. Research shows that patients in both complete and partial remission have a much lower risk of their disease progressing to End-Stage Renal Disease (ESRD) compared to those whose protein levels remain high [4][5]. However, remission does not guarantee stable eGFR, and the meaning of partial remission depends on the cause and starting kidney function; proteinuria and eGFR must be followed together.

Daily Management Strategies

Managing FSGS at home focuses on reducing the stress on your kidneys and monitoring for changes.

  • Blood Pressure Control: High blood pressure acts like a “pressure cooker” for your kidney filters [6]. Contemporary KDIGO blood-pressure guidance uses a standardized office systolic target below 120 mmHg when tolerated for many adults with CKD, while home measurements may use different targets. Your doctor will personalize this goal for you [7].
  • Sodium (Salt) Intake: Eating less salt helps your body hold onto less fluid, which reduces swelling (edema) and lowers blood pressure [6]. Aim for a “sodium-conscious” diet by avoiding processed foods and not adding extra salt at the table.
  • Monitoring: Your doctor will likely request regular blood and urine tests to monitor your eGFR (a measure of how well your kidneys are filtering) and your protein levels [5]. If you are on RAAS blockade (ACE inhibitors or ARBs), they will also check your potassium levels frequently, as these drugs can sometimes cause potassium to rise [8][9].

Prognosis and Progression

“Prognosis” is a medical term for the likely course of a disease. In FSGS, several factors influence whether the disease will stay stable or lead to kidney failure [1]:

  • Baseline Function: How well your kidneys were working at the time of diagnosis [1].
  • The Biopsy: The amount of existing scarring seen on your biopsy (interstitial fibrosis) can provide clues about how much “reserve” your kidneys have left [1].
  • Response to Treatment: As mentioned, how much your protein levels drop during treatment is the strongest sign of a positive outlook [5].

Looking Toward Transplantation

If FSGS eventually leads to kidney failure, a kidney transplant is often the best option for restoring health and quality of life. However, there is a crucial distinction between the different types of FSGS when it comes to a new kidney [10]:

  • Primary FSGS: Because this type is thought to be caused by a factor in the blood, it can return (recur) in the new kidney. The recurrence risk varies with diagnostic certainty, age, and prior transplants, but can range from 30% to 40% (and may be higher in children) [11][12]. If it does recur, it often happens early [13].
  • Genetic and Secondary FSGS: The risk of these forms returning in a new kidney is considered very low, though not absolute zero [11][10]. This is because the original cause—such as an intrinsic genetic mutation or a structural stressor—is usually not present in the donor kidney, although persistent systemic causes like obesity can still injure an allograft.

Knowing your specific “type” of FSGS early on helps you and your transplant team create a monitoring plan to catch any recurrence early, when it is most treatable [14].

Common questions in this guide

What does remission mean in FSGS?
Complete remission means urine protein has fallen to near-normal levels, often measured as a urine protein-to-creatinine ratio below 0.3 g/g. Partial remission generally means urine protein has fallen by at least 50% and remains around 0.3 to 3.5 g/g. Both are associated with a lower risk of kidney failure than persistently high proteinuria, but remission does not guarantee stable kidney function.
How is FSGS monitored over time?
Clinicians typically follow urine protein and eGFR, a measure of kidney filtering, with regular urine and blood tests. Blood pressure and symptoms such as swelling or changes in urine may also be tracked. People taking an ACE inhibitor or ARB may need regular potassium and kidney-function checks because these medicines can raise potassium in some people.
What blood pressure target is appropriate for someone with FSGS?
The target is individualized based on factors such as age, kidney function, proteinuria, and how well treatment is tolerated. Contemporary guidance often uses a standardized office systolic target below 120 mmHg for many adults with chronic kidney disease, while home readings may use different targets. Ask your clinician which goal applies to your measurements.
What factors affect the prognosis of FSGS?
The main factors discussed on this page are kidney function at diagnosis, the amount of scarring seen on biopsy, and the response to treatment. A substantial reduction in urine protein is generally a favorable sign, but urine protein and eGFR need to be considered together because remission does not always mean kidney function will remain stable.
Can FSGS return after a kidney transplant?
Primary FSGS can recur in a transplanted kidney, often early after transplantation, and reported risk commonly ranges from about 30% to 40% but varies by diagnostic certainty, age, and transplant history. Genetic and secondary FSGS have a very low, though not zero, recurrence risk because the original cause is usually not present in the donor kidney. Persistent systemic factors such as obesity can still harm a transplanted kidney.
What can I do day to day to manage FSGS?
A sodium-conscious diet, including fewer processed foods and less added salt, can help reduce fluid retention and blood pressure. Keeping a log of blood pressure, swelling, and urine changes can help you and your care team notice trends. Continue the monitoring and medication plan prescribed by your clinicians.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Focal segmental glomerulosclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my latest tests, am I in complete remission, partial remission, or neither?
  2. 2.What specific blood pressure target is right for me, given my age and the amount of protein I am losing?
  3. 3.What is my current eGFR slope, and what does it tell us about how quickly my kidney function is changing?
  4. 4.If I need a transplant in the future, how does my specific 'type' of FSGS (primary vs. secondary/genetic) affect the risk of the disease returning?
  5. 5.How often should we be checking my potassium levels and kidney function while I am on blood pressure medications?

References

References (14)
  1. 1

    Clinical presentation, treatment and outcome of focal segmental glomerulosclerosis in Far North Queensland Australian adults.

    Greenwood AM, Gunnarsson R, Neuen BL, et al.

    Nephrology (Carlton, Vic.) 2017; (22(7)):520-530 doi:10.1111/nep.12816.

    PMID: 27170059
  2. 2

    An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis.

    Troost JP, Trachtman H, Nachman PH, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2018; (13(3)):414-421 doi:10.2215/CJN.04780517.

    PMID: 29167190
  3. 3

    The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case-series.

    Kashgary A, Sontrop JM, Li L, et al.

    BMC nephrology 2016; (17(1)):104 doi:10.1186/s12882-016-0322-7.

    PMID: 27473582
  4. 4

    Renal survival and treatment of adult patients with Primary Focal Segmental glomerulosclerosis: A historical cohort study of the National Greek Registry.

    Marinaki S, Kompotiatis P, Michelakis I, et al.

    PloS one 2024; (19(12)):e0315124 doi:10.1371/journal.pone.0315124.

    PMID: 39693288
  5. 5

    Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis.

    Troost JP, Trachtman H, Spino C, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2021; (77(2)):216-225 doi:10.1053/j.ajkd.2020.04.014.

    PMID: 32791086
  6. 6

    Chronic kidney disease.

    Kalantar-Zadeh K, Jafar TH, Nitsch D, et al.

    Lancet (London, England) 2021; (398(10302)):786-802 doi:10.1016/S0140-6736(21)00519-5.

    PMID: 34175022
  7. 7

    Adherence to the Kidney Disease: Improving Global Outcomes CKD Guideline in Nephrology Practice Across Countries.

    Stengel B, Muenz D, Tu C, et al.

    Kidney international reports 2021; (6(2)):437-448 doi:10.1016/j.ekir.2020.11.039.

    PMID: 33615069
  8. 8

    Clinical Management of Hyperkalemia.

    Palmer BF, Carrero JJ, Clegg DJ, et al.

    Mayo Clinic proceedings 2021; (96(3)):744-762 doi:10.1016/j.mayocp.2020.06.014.

    PMID: 33160639
  9. 9

    Optimizing renin-angiotensin-aldosterone inhibition in advanced chronic kidney disease: balancing benefits and risks.

    Spencer S, Bhandari S

    Current opinion in nephrology and hypertension 2025; (34(6)):469-476 doi:10.1097/MNH.0000000000001076.

    PMID: 40207744
  10. 10

    Recurrence and Treatment after Renal Transplantation in Children with FSGS.

    Kang HG, Ha IS, Cheong HI

    BioMed research international 2016; (2016()):6832971 doi:10.1155/2016/6832971.

    PMID: 27213154
  11. 11

    Incidence and risk factors for recurrent focal segmental glomerulosclerosis after kidney transplantation: a meta-analysis.

    Bai J, Zhang T, Wang Y, et al.

    Renal failure 2023; (45(1)):2201341 doi:10.1080/0886022X.2023.2201341.

    PMID: 37070350
  12. 12

    Incidence, risk factors, and outcomes of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: A systematic review and meta-analysis.

    Bai J, Yin X, Li J, et al.

    Clinical transplantation 2023; (37(11)):e15119 doi:10.1111/ctr.15119.

    PMID: 37725070
  13. 13

    Therapeutic Options for Recurrence of Primary Focal Segmental Glomerulonephritis (FSGS) in the Renal Allograft: Single-Center Experience.

    Vallianou K, Marinaki S, Skalioti C, et al.

    Journal of clinical medicine 2021; (10(3)) doi:10.3390/jcm10030373.

    PMID: 33498160
  14. 14

    Kidney Transplantation for Focal Segmental Glomerulosclerosis: Can We Prevent Its Recurrence? Personal Experience and Literature Review.

    Naciri Bennani H, Elimby L, Terrec F, et al.

    Journal of clinical medicine 2021; (11(1)) doi:10.3390/jcm11010093.

    PMID: 35011834

This page is for informational purposes only and does not constitute medical advice. Your nephrologist and transplant team can interpret your results and recommend monitoring for your specific situation.